search
Back to results

Erbium Vaginal Laser for the Treatment of Stress Urinary Incontinence

Primary Purpose

Stress Urinary Incontinence

Status
Unknown status
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
Erbium laser
Sham laser
Sponsored by
Rambam Health Care Campus
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Stress Urinary Incontinence

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

women above 18 with SUI -

Exclusion Criteria:

  1. Recurrent pelvic inflammatory disease
  2. Vaginal operation in the previous year
  3. Women with abnormal uterine bleeding
  4. Women with diagnosed genital herpes infection
  5. Any concurrent lower genital tract infection -

Sites / Locations

  • Rambam Health Care CampusRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Sham Comparator

Arm Label

Erbium laser

Sham laser

Arm Description

Treatment with Erbium laser

Treatment with sham laser

Outcomes

Primary Outcome Measures

Cough test
Results of full bladder cough test
Pad test
Results of 24 hour pad weighing test

Secondary Outcome Measures

Urinary distress index 6
Results of Urinary distress index 6 questionnaire
Female sexual function
Results of female sexual function index questionnaire
Urinary incontinence and sexuality
Results of urinary incontinence and sexuality questionnaire

Full Information

First Posted
November 10, 2020
Last Updated
March 9, 2021
Sponsor
Rambam Health Care Campus
search

1. Study Identification

Unique Protocol Identification Number
NCT04636749
Brief Title
Erbium Vaginal Laser for the Treatment of Stress Urinary Incontinence
Official Title
Erbium Vaginal Laser for the Treatment of Stress Urinary Incontinence - Randomized Single Blind Trial
Study Type
Interventional

2. Study Status

Record Verification Date
March 2021
Overall Recruitment Status
Unknown status
Study Start Date
March 9, 2021 (Actual)
Primary Completion Date
October 22, 2022 (Anticipated)
Study Completion Date
October 22, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Rambam Health Care Campus

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Two arms of women who suffer from clinical stress urinary incontinence. Women will be divided randomly into two arms. One arm will be treated with vaginal Erbium laser and the second with Sham laser, three treatments each. Follow up will be done 6 and 12 months after the last treatment.
Detailed Description
Examine the efficacy of vaginal Erbium laser treatment for stress urinary incontinence (SUI) in compare to placebo. Plenty of women suffer from SUI. It is a condition in which involuntary urine leakage occurs during exercise. This condition affects about 40% of all women and causes huge disturbance to daily life. There are plenty of risk factors, such as age, obesity and parity. We assume that the pathophysiology is related to hypermobility of the urethra due to damage to the surrounding tissue. The treatment options vary from surgical interventional to conservative, each treatment has its own success rate and risk factors. An attempt to find effective treatment option has been made. The use of laser for various gynecologic conditions are at rise. ERBIUM type laser works on the lamina propria layer and causes rejuvenation probably by strengthening collagen structures and creating new ones. The efficacy and safety of vaginal laser therapy has been proven already, but in the field of SUI the numbers in each study were low and there was no control group. In this study we desire to examine the effect of vaginal ERBIUM treatment on SUI in compare to placebo. this is a randomized single blind control trial. 40 women will be included in the research group and 40 in the placebo group. Women will be assigned randomly to each group. They will be treated with vaginal laser probe, three treatments 4 weeks apart. Follow up visits will be performed 3, 6, and 12 months after the first treatment. Effectiveness evaluation will be done by physical urodynamic examination before treatment and 6 month after finishing, by 24 hours pad test' cough test and by fulfilling questionnaires- The Urogenital Distress inventory (UDI6) The Female Sexual Function Index (FSFI)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stress Urinary Incontinence

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
80 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Erbium laser
Arm Type
Active Comparator
Arm Description
Treatment with Erbium laser
Arm Title
Sham laser
Arm Type
Sham Comparator
Arm Description
Treatment with sham laser
Intervention Type
Device
Intervention Name(s)
Erbium laser
Intervention Description
Vaginal laser therapy
Intervention Type
Device
Intervention Name(s)
Sham laser
Intervention Description
Sham laser therapy
Primary Outcome Measure Information:
Title
Cough test
Description
Results of full bladder cough test
Time Frame
From enrollment up to 12 months post treatment
Title
Pad test
Description
Results of 24 hour pad weighing test
Time Frame
From enrollment up to 12 months post treatment
Secondary Outcome Measure Information:
Title
Urinary distress index 6
Description
Results of Urinary distress index 6 questionnaire
Time Frame
From enrollment up to 12 months post treatment
Title
Female sexual function
Description
Results of female sexual function index questionnaire
Time Frame
From enrollment up to 12 months post treatment
Title
Urinary incontinence and sexuality
Description
Results of urinary incontinence and sexuality questionnaire
Time Frame
From enrollment up to 12 months post treatment

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: women above 18 with SUI - Exclusion Criteria: Recurrent pelvic inflammatory disease Vaginal operation in the previous year Women with abnormal uterine bleeding Women with diagnosed genital herpes infection Any concurrent lower genital tract infection -
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Naama Farago, MD
Phone
972-509267806
Email
n_farago@rmc.gov.il
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Naama Farago, MD
Organizational Affiliation
Rambam Health Care Campus
Official's Role
Principal Investigator
Facility Information:
Facility Name
Rambam Health Care Campus
City
Haifa
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
NAAMA FARAGO, DR
Phone
+972-4-7772201
Email
N_FARAGO@RMC.GOV.IL

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
26366798
Citation
Cervigni M, Gambacciani M. Female urinary stress incontinence. Climacteric. 2015;18 Suppl 1:30-6. doi: 10.3109/13697137.2015.1090859.
Results Reference
background
PubMed Identifier
25078140
Citation
Padmanabhan P, Dmochowski R. Urinary incontinence in women: a comprehensive review of the pathophysiology, diagnosis and treatment. Minerva Ginecol. 2014 Oct;66(5):469-78. Epub 2014 Jul 31.
Results Reference
background
PubMed Identifier
30773062
Citation
Itkonen Freitas AM, Rahkola-Soisalo P, Mikkola TS, Mentula M. Current treatments for female primary stress urinary incontinence. Climacteric. 2019 Jun;22(3):263-269. doi: 10.1080/13697137.2019.1568404. Epub 2019 Feb 18.
Results Reference
background
PubMed Identifier
28625508
Citation
Kobashi KC, Albo ME, Dmochowski RR, Ginsberg DA, Goldman HB, Gomelsky A, Kraus SR, Sandhu JS, Shepler T, Treadwell JR, Vasavada S, Lemack GE. Surgical Treatment of Female Stress Urinary Incontinence: AUA/SUFU Guideline. J Urol. 2017 Oct;198(4):875-883. doi: 10.1016/j.juro.2017.06.061. Epub 2017 Jun 15.
Results Reference
background
PubMed Identifier
30503362
Citation
Dwyer PL, Karmakar D. Surgical management of urinary stress incontinence - Where are we now? Best Pract Res Clin Obstet Gynaecol. 2019 Jan;54:31-40. doi: 10.1016/j.bpobgyn.2018.10.003. Epub 2018 Oct 30.
Results Reference
background
PubMed Identifier
31990055
Citation
Saraswat L, Rehman H, Omar MI, Cody JD, Aluko P, Glazener CM. Traditional suburethral sling operations for urinary incontinence in women. Cochrane Database Syst Rev. 2020 Jan 28;1(1):CD001754. doi: 10.1002/14651858.CD001754.pub5.
Results Reference
background
PubMed Identifier
10685095
Citation
Majaron B, Srinivas SM, Huang He, Nelson JS. Deep coagulation of dermal collagen with repetitive Er:YAG laser irradiation. Lasers Surg Med. 2000;26(2):215-22. doi: 10.1002/(sici)1096-9101(2000)26:23.0.co;2-o.
Results Reference
background
PubMed Identifier
11074514
Citation
Greene D, Egbert BM, Utley DS, Koch RJ. In vivo model of histologic changes after treatment with the superpulsed CO(2) laser, erbium:YAG laser, and blended lasers: a 4- to 6-month prospective histologic and clinical study. Lasers Surg Med. 2000;27(4):362-72. doi: 10.1002/1096-9101(2000)27:43.0.co;2-h.
Results Reference
background
PubMed Identifier
26366793
Citation
Vizintin Z, Lukac M, Kazic M, Tettamanti M. Erbium laser in gynecology. Climacteric. 2015;18 Suppl 1:4-8. doi: 10.3109/13697137.2015.1078668.
Results Reference
background
PubMed Identifier
30687908
Citation
Okui N. Efficacy and safety of non-ablative vaginal erbium:YAG laser treatment as a novel surgical treatment for overactive bladder syndrome: comparison with anticholinergics and beta3-adrenoceptor agonists. World J Urol. 2019 Nov;37(11):2459-2466. doi: 10.1007/s00345-019-02644-7. Epub 2019 Jan 28.
Results Reference
background
PubMed Identifier
28770296
Citation
Pergialiotis V, Prodromidou A, Perrea DN, Doumouchtsis SK. A systematic review on vaginal laser therapy for treating stress urinary incontinence: Do we have enough evidence? Int Urogynecol J. 2017 Oct;28(10):1445-1451. doi: 10.1007/s00192-017-3437-x. Epub 2017 Aug 2.
Results Reference
background
PubMed Identifier
30523374
Citation
Shobeiri SA, Kerkhof MH, Minassian VA, Bazi T; IUGA Research and Development Committee. IUGA committee opinion: laser-based vaginal devices for treatment of stress urinary incontinence, genitourinary syndrome of menopause, and vaginal laxity. Int Urogynecol J. 2019 Mar;30(3):371-376. doi: 10.1007/s00192-018-3830-0. Epub 2018 Dec 6.
Results Reference
background
PubMed Identifier
29360142
Citation
Fistonic I, Fistonic N. Baseline ICIQ-UI score, body mass index, age, average birth weight, and perineometry duration as promising predictors of the short-term efficacy of Er:YAG laser treatment in stress urinary incontinent women: A prospective cohort study. Lasers Surg Med. 2018 Jan 23. doi: 10.1002/lsm.22789. Online ahead of print.
Results Reference
background
PubMed Identifier
31542080
Citation
Su CF, Chen GD, Tsai HJ. Preliminary outcome of non-ablative vaginal Erbium laser treatment for female stress and mixed urinary incontinence. Taiwan J Obstet Gynecol. 2019 Sep;58(5):610-613. doi: 10.1016/j.tjog.2019.07.006.
Results Reference
background
PubMed Identifier
26388213
Citation
Ogrinc UB, Sencar S, Lenasi H. Novel minimally invasive laser treatment of urinary incontinence in women. Lasers Surg Med. 2015 Nov;47(9):689-97. doi: 10.1002/lsm.22416. Epub 2015 Sep 21.
Results Reference
background
PubMed Identifier
29033365
Citation
Conte C, Jauffret T, Vieillefosse S, Hermieu JF, Deffieux X. Laser procedure for female urinary stress incontinence: A review of the literature. Prog Urol. 2017 Dec;27(17):1076-1083. doi: 10.1016/j.purol.2017.09.003. Epub 2017 Oct 21.
Results Reference
background
PubMed Identifier
30766886
Citation
Lin KL, Chou SH, Long CY. Effect of Er:YAG Laser for Women with Stress Urinary Incontinence. Biomed Res Int. 2019 Jan 15;2019:7915813. doi: 10.1155/2019/7915813. eCollection 2019.
Results Reference
background
PubMed Identifier
26366800
Citation
Gambacciani M, Torelli MG, Martella L, Bracco GL, Casagrande AG, Albertin E, Tabanelli S, Viglietta M, D'Ambrogio G, Garone G, Cervigni M. Rationale and design for the Vaginal Erbium Laser Academy Study (VELAS): an international multicenter observational study on genitourinary syndrome of menopause and stress urinary incontinence. Climacteric. 2015;18 Suppl 1:43-8. doi: 10.3109/13697137.2015.1071608.
Results Reference
background
PubMed Identifier
29241926
Citation
Lin YH, Hsieh WC, Huang L, Liang CC. Effect of non-ablative laser treatment on overactive bladder symptoms, urinary incontinence and sexual function in women with urodynamic stress incontinence. Taiwan J Obstet Gynecol. 2017 Dec;56(6):815-820. doi: 10.1016/j.tjog.2017.10.020.
Results Reference
background
PubMed Identifier
30545535
Citation
Lin HY, Tsai HW, Tsui KH, An YF, Lo CC, Lin ZH, Liou WS, Wang PH. The short-term outcome of laser in the management of female pelvic floor disorders: Focus on stress urine incontinence and sexual dysfunction. Taiwan J Obstet Gynecol. 2018 Dec;57(6):825-829. doi: 10.1016/j.tjog.2018.10.010.
Results Reference
background

Learn more about this trial

Erbium Vaginal Laser for the Treatment of Stress Urinary Incontinence

We'll reach out to this number within 24 hrs